Loading...
Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations
The routine use of recombinant erythropoiesis-stimulating agents (ESA) over the past three decades has enabled the partial correction of anaemia in most patients with end-stage renal disease (ESRD). Since ESA use frequently leads to iron deficiency, almost all ESA-treated haemodialysis patients worl...
Saved in:
| Published in: | Heliyon |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Elsevier
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6627982/ https://ncbi.nlm.nih.gov/pubmed/31338466 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.heliyon.2019.e02045 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|